State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....

HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...

Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...

Zydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...

In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...

Global lenders are exploring various financing options for Sun Pharmaceutical Industries' proposed $12 billion acquisition of Organon & Co....

Sun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...

Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...

Sun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...

Bain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...

Soleno Therapeutics has withdrawn its European drug application. This decision stems from its acquirer, Neurocrine Biosciences, prioritizin...

This is the second pharma merger and acquisition (M&A) transaction that has been called off or postponed recently due to market volatility ...

Last week, the court had vacated the status quo order it had issued earlier on the merger process between Sun Pharma and Ranbaxy.

The Andhra Pradesh high court on Saturday vacated stay orders it issued last month on the merger of two firms that would create world’s fou...

The court had earlier issued interim orders to maintain status quo with regard to the merger.

Two individual investors alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6.

The $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo said.